Literature DB >> 28450268

Extensive uptake of α-synuclein oligomers in astrocytes results in sustained intracellular deposits and mitochondrial damage.

Veronica Lindström1, Gabriel Gustafsson2, Laurie H Sanders3, Evan H Howlett3, Jessica Sigvardson4, Alex Kasrayan4, Martin Ingelsson2, Joakim Bergström2, Anna Erlandsson2.   

Abstract

The presence of Lewy bodies, mainly consisting of aggregated α-synuclein, is a pathological hallmark of Parkinson's disease (PD) and dementia with Lewy bodies (DLB). The α-synuclein inclusions are predominantly found in neurons, but also appear frequently in astrocytes. However, the pathological significance of α-synuclein inclusions in astrocytes and the capacity of glial cells to clear toxic α-synuclein species remain unknown. In the present study we investigated uptake, degradation and toxic effects of oligomeric α-synuclein in a co-culture system of primary neurons, astrocytes and oligodendrocytes. Alpha-synuclein oligomers were found to co-localize with the glial cells and the astrocytes were found to internalize particularly large amounts of the protein. Following ingestion, the astrocytes started to degrade the oligomers via the lysosomal pathway but, due to incomplete digestion, large intracellular deposits remained. Moreover, the astrocytes displayed mitochondrial abnormalities. Taken together, our data indicate that astrocytes play an important role in the clearance of toxic α-synuclein species from the extracellular space. However, when their degrading capacity is overburdened, α-synuclein deposits can persist and result in detrimental cellular processes.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Astrocytes; Glia; Mitochondria; Oligodendrocytes; Parkinson's disease; α-Synuclein oligomers

Mesh:

Substances:

Year:  2017        PMID: 28450268     DOI: 10.1016/j.mcn.2017.04.009

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  60 in total

Review 1.  The A1 astrocyte paradigm: New avenues for pharmacological intervention in neurodegeneration.

Authors:  Jared T Hinkle; Valina L Dawson; Ted M Dawson
Journal:  Mov Disord       Date:  2019-05-28       Impact factor: 10.338

Review 2.  Protein astrogliopathies in human neurodegenerative diseases and aging.

Authors:  Gabor G Kovacs; Virginia M Lee; John Q Trojanowski
Journal:  Brain Pathol       Date:  2017-09       Impact factor: 6.508

Review 3.  The unlikely partnership between LRRK2 and α-synuclein in Parkinson's disease.

Authors:  Noémie Cresto; Camille Gardier; Francesco Gubinelli; Marie-Claude Gaillard; Géraldine Liot; Andrew B West; Emmanuel Brouillet
Journal:  Eur J Neurosci       Date:  2018-10-24       Impact factor: 3.386

Review 4.  Astrocyte and Alzheimer's disease.

Authors:  Zhiyou Cai; Cheng-Qun Wan; Zhou Liu
Journal:  J Neurol       Date:  2017-08-18       Impact factor: 4.849

5.  Creating a graft-friendly environment for stem cells in diseased brains.

Authors:  Robert Yl Tsai
Journal:  J Clin Invest       Date:  2017-12-11       Impact factor: 14.808

6.  Astroglial Responses to Amyloid-Beta Progression in a Mouse Model of Alzheimer's Disease.

Authors:  Malin Olsen; Ximena Aguilar; Dag Sehlin; Xiaotian T Fang; Gunnar Antoni; Anna Erlandsson; Stina Syvänen
Journal:  Mol Imaging Biol       Date:  2018-08       Impact factor: 3.488

Review 7.  α-Synuclein and astrocytes: tracing the pathways from homeostasis to neurodegeneration in Lewy body disease.

Authors:  Zachary A Sorrentino; Benoit I Giasson; Paramita Chakrabarty
Journal:  Acta Neuropathol       Date:  2019-02-23       Impact factor: 17.088

8.  Lysosome and Inflammatory Defects in GBA1-Mutant Astrocytes Are Normalized by LRRK2 Inhibition.

Authors:  Anwesha Sanyal; Mark P DeAndrade; Hailey S Novis; Steven Lin; Jianjun Chang; Nathalie Lengacher; Julianna J Tomlinson; Malú G Tansey; Matthew J LaVoie
Journal:  Mov Disord       Date:  2020-02-08       Impact factor: 10.338

9.  Crosstalk between astrocytes and microglia results in increased degradation of α-synuclein and amyloid-β aggregates.

Authors:  Jinar Rostami; Tobias Mothes; Mahshad Kolahdouzan; Olle Eriksson; Mohsen Moslem; Joakim Bergström; Martin Ingelsson; Paul O'Callaghan; Luke M Healy; Anna Falk; Anna Erlandsson
Journal:  J Neuroinflammation       Date:  2021-06-03       Impact factor: 8.322

Review 10.  Innovative treatment targeting gangliosides aimed at blocking the formation of neurotoxic α-synuclein oligomers in Parkinson's disease.

Authors:  Nouara Yahi; Coralie Di Scala; Henri Chahinian; Jacques Fantini
Journal:  Glycoconj J       Date:  2021-07-30       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.